<DOC>
	<DOCNO>NCT01380561</DOCNO>
	<brief_summary>This open label , single center , metabolite identification , mass balance , PK study healthy male volunteer .</brief_summary>
	<brief_title>A Metabolite Identification , Mass Balance , PK Study 14C-Asimadoline Healthy Adult Male Volunteers</brief_title>
	<detailed_description>This open label , single center , metabolite identification , mass balance , PK study healthy male volunteer . The purpose study determine excretion total [ 14C ] derive radioactivity metabolite profile single oral dose [ 14C ] asimadoline well identify quantitate metabolite asimadoline plasma , urine , feces single multiple oral dos asimadoline .</detailed_description>
	<criteria>Be inform nature study provide write informed voluntary consent Be healthy male , least 18 year age legal age consent ( whichever great ) less 56 year age Have body mass index ( BMI ) &gt; =18.0 &lt; 32.0 kg/m2 weigh least 50 kg Be good general health clinically relevant abnormality base medical history , physical examination , clinical laboratory evaluation ( hematology , clinical chemistry , urinalysis ) , 12 lead electrocardiogram ( ECG ) , opinion Investigator , would affect subject safety Agree comply study procedure restriction . Any disease condition might affect drug absorption , metabolism , excretion , clinically significant cardiovascular , hematological , renal , hepatic , pulmonary , endocrine , gastrointestinal , immunological , dermatological , neurological , psychiatric disease Receipt radioisotope effective halflife 30 day within previous 12 month Receipt diagnostic radiation procedure effective dose exceed 1 rem lifetime Occupational exposure radiation ( e.g. , routinely require wear radiation monitoring badge ) Receipt radiation treatments/therapy History constipation infrequent bowel movement ( &lt; =6 bowel movement per week average ) Known suspect hypersensitivity allergic reaction asimadoline similar chemical compound component asimadoline tablet Chronic use systemic medication ( exception vitamins take standard supplement dos ) ; use drug therapy ( include herbal preparation , e.g. , St. John 's wort ) know induce inhibit hepatic drug metabolism within 30 day first dose study medication ; use prescription medication within 14 day administration study medication overthecounter product ( include natural product ) within 7 day administration study medication , except topical product without systemic absorption , unless approve Sponsor Have smoke cigarette use nicotinecontaining product last 3 month able abstain smoke duration confinement period If sterile , agree use one follow approve method contraception , checkin 3 month follow Study Completion/Clinic Discharge : male condom spermicide ; sterile sexual partner ; use female sexual partner intrauterine device spermicide ; female condom spermicide ; contraceptive sponge spermicide ; cervical cap spermicide ; oral , implantable , transdermal , injectable contraceptive reliable secondary backup method Current history evidence drug alcohol abuse positive screen substance abuse alcohol screen admission Positive screen hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody Receipt investigational product device , participation drug research study within period 30 day ( 5 half life drug , whichever long ) first dose study medication Blood loss blood donation &gt; 550 mL within 90 day plasma donation &gt; 500 mL within 30 day administration study drug Any food allergy , intolerance , restriction , special diet , opinion Investigator , preclude subject 's participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>56 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>asimadoline</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>excretion 14C-derived radioactivity</keyword>
	<keyword>metabolite profile</keyword>
	<keyword>14C-asimadoline</keyword>
	<keyword>metabolite</keyword>
	<keyword>single multiple oral dos</keyword>
</DOC>